Exogenous Surfactant in Very Preterm Neonates in Prevention of Bronchopulmonary Dysplasia
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Advances in perinatal care have made it possible to improve the survival of the most immature
neonates, but at the cost of an increase in the population at risk of developing
bronchopulmonary dysplasia (BPD). Measures that have attempted to limit the development of
BPD are not always effective, or related to major side effects. The physiopathological
factors that are identified in BPD should, in theory, respond to surfactant. Therefore, the
use of an exogenous surfactant in neonates presenting with pulmonary disease requiring
mechanical ventilation, leading to a significant risk of BPD, should allow earlier extubation
and thus promote pulmonary healing and growth.